title: [A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
abstract: A man in his early seventies underwent low anterior resection and partial resection of the liver for the rectal cancer and liver metastasis. However, 4 months after the surgery, he was found to have a liver tumor at S5 and S7 by abdominal CT scan. Then, he underwent chemotherapy (mFOLFOX6), but the metastatic tumor was progressive. We selected FOLFIRI + cetuximab regimen for second-line therapy to resect the metastatic tumor. As the metastatic lesion was become smaller after 4-course of the regimen including cetuximab, we decided to perform a radical resection. We conducted a right lobectomy of the liver, and the tumor was completely resected.
authors.affiliation: Dept. of Surgery, Kenseikai Nara Coloproctology Center.
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Shimobayashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Inatsugi
authors.forename: Shusaku
authors.initials: S
authors.lastname: Yoshikawa
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masuda
authors.forename: Hideki
authors.initials: H
authors.lastname: Uchida
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuge
authors.forename: Tomoyo
authors.initials: T
authors.lastname: Yokotani
authors.forename: Takaya
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kawaguchi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamaoka
authors.forename: Mizumi
authors.initials: M
authors.lastname: Inagaki
authors.forename: Masaki
authors.initials: M
authors.lastname: Matsuoka
authors.forename: Koichi
authors.initials: K
authors.lastname: Tatsumi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Saraya
authors.forename: Toshio
authors.initials: T
authors.lastname: Otsuji
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamochi
authors.forename: Kozo
authors.initials: K
authors.lastname: Yamanishi
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Enomoto
authors.forename: Akitaka
authors.initials: A
authors.lastname: Nonomura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Sho
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Nakajima
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin